This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will Buyouts Help Quest Diagnostics (DGX) Beat Q1 Earnings?
by Zacks Equity Research
Quest Diagnostics' (DGX) successful strategies to build esoteric testing business and boost profit margins raise optimism among investors on the stock.
What's in Store for GNC Holdings (GNC) This Earnings Season?
by Zacks Equity Research
GNC Holdings (GNC) likely to witness year-over-year decline in revenues owing to weakness in the U.S. & Canada and Manufacturing/Wholesale segments in Q1.
Is Quest Diagnostics a Great Stock for Value Investors?
by Zacks Equity Research
Let's see if Quest Diagnostics Inc. (DGX) stock is a good choice for value-oriented investors right now from multiple angles.
Quest Diagnostics Banks on Alliances, Long-Term View Solid
by Zacks Equity Research
Quest Diagnostics (DGX) grows on infectious disease testing, prescription drug monitoring and wellness business. New collaborations with hospitals and integrated delivery networks are other positives.
Quest Diagnostics (DGX) Tops Q4 Earnings, Revenues Estimates
by Zacks Equity Research
Quest Diagnostics' (DGX) full year 2018 guidance is aligned with the company's long term outlook.
Quest Diagnostics to Buy MedXM, Boost Home Health Services
by Zacks Equity Research
Quest Diagnostics (DGX) actively pursues mergers and acquisitions to strengthen hold in the high-potential global home healthcare market.
What to Expect From Quest Diagnostics (DGX) in Q4 Earnings
by Zacks Equity Research
Quest Diagnostics (DGX) spots a slight turnaround of its sluggish revenue per requisition performance only in the last couple of quarters.
Abbott Boosts Diagnostics Arm With Alinity H-Series Launch
by Zacks Equity Research
Abbott (ABT) adopts initiatives to strengthen hold in the high-potential diagnostics market.
Quest Diagnostics, LabCorp Defend Lab Fee Suit Against HHS
by Zacks Equity Research
Quest Diagnostics (DGX) and LabCorp (LH) join forces to back a case slapped on HHS for unable to follow a congressional directive to devise a market-based laboratory payment system.
Quest Diagnostics Buys Fresenius Medical's Shiel Laboratory
by Zacks Equity Research
Quest Diagnostics (DGX) focuses on driving growth and operational efficiency through acquisitions.
Myriad Genetics Presents Encouraging EndoPredict Test Data
by Zacks Equity Research
Myriad Genetics (MYGN) forges ahead with initiatives to boost the Molecular Diagnostics portfolio.
Myriad Genetics (MYGN) Presents Positive riskScore Test Data
by Zacks Equity Research
Myriad Genetics (MYGN) presents positive riskScore data at the SABCS. With riskScore, the company intends to boost its myRisk Hereditary Cancer test suite.
Top Research Reports for Bank of America, Celgene & Goldman Sachs
by Zacks Equity Research
Today's Research Daily features new research reports on 16 major stocks, including Bank of America (BAC), Celgene (CELG) and Goldman Sachs (GS).
Quest Diagnostics Banks on Buyouts to Expand in Diagnostic
by Zacks Equity Research
Quest Diagnostics (DGX) actively pursues merger and acquisitions to solidify hold in the high-potential diagnostic information services market. Notably, Cleveland HeartLab buyout marks as the latest deal.
Quest Diagnostics (DGX) Tops Q3 Earnings, Revenues In Line
by Zacks Equity Research
Considering hurricanes related financial impact and recently-closed acquisitions, Quest Diagnostics' (DGX) management has revised its guidance for full year 2017.
Will Quest Diagnostics (DGX) Disappoint in Q3 Earnings?
by Zacks Equity Research
The overall soft industry trends leading to low volume environment may continue to put a dampener on Quest Diagnostics (DGX) in Q3. The reimbursement scenario also remains a major cause for concern.
Is Quest Diagnostics (DGX) a Great Stock for Value Investors?
by Zacks Equity Research
Let's see if Quest Diagnostics (DGX) stock is a good choice for value-oriented investors right now from multiple angles.
Why Is Quest Diagnostics (DGX) Down 3.9% Since the Last Earnings Report?
by Zacks Equity Research
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amedisys (AMED) Earnings & Revenues Miss Estimates in Q2
by Zacks Equity Research
Strength in Hospice and Personal Care businesses offset the weakness in Amedisys' (AMED) Home Health Medicare business in Q2.
Edwards Lifesciences (EW) Tops Q2 Earnings & Sales, View Up
by Zacks Equity Research
Edwards Lifesciences (EW) rides high on continued growth in its highly advanced Transcatheter Heart Valve space in Q2.
Thermo Fisher (TMO) Tops Q2 Earnings & Revenues, View Up
by Zacks Equity Research
Thermo Fisher Scientific (TMO) continues to gain considerable synergies from FEI Company acquisition. A raised guidance buoys optimism.
Quest Diagnostics (DGX) Tops Q2 Earnings, Raises '17 View
by Zacks Equity Research
Quest Diagnostics (DGX) continues to ride high on its advanced diagnostic offerings. Also, a raised view buoys optimism.
Quest Diagnostics (DGX) Tops Q2 Earnings, Misses on Sales
by Zacks Equity Research
Quest Diagnostics (DGX) gains in Q2 banking on the acquisition of Med Fusion and ClearPoint.
Healthcare Q2 Earnings Slated on Jul 25: HCA, UHS & More
by Zacks Equity Research
The healthcare sector continues to benefit from higher enrollments, mergers and acquisitions, partly offset by high expense on account of acquisition integration and investments in technology.
Quest Diagnostics Closes Deal to Acquire 2 Labs in Texas
by Zacks Equity Research
Quest Diagnostics (DGX) acquires Med Fusion and Clear Point lab businesses to grow in oncology space.